Skip to main content
< Back
About
About the conference
App
Organisers & Partners
Latest updates
Press room
Registration
Venue 22
About the venue
Rooms
Call for abstracts
Programme 22
Tracks 22
Speakers 22
Side events 22
Subscribe
days
hours
minutes
seconds
Harm reduction
Sessions
Wednesday, 23 November
10:50
Drug treatment
10:50
to
12:20
Knowledge market 3 (K3)
Oral presentation session
Reaching out
10:50
to
12:20
Networking zone 4 (N4)
Short communication session
13:20
Drug use in diverse communities and settings
13:20
to
14:50
Networking zone 1 (N1)
e-poster guided tour
Migration, substance use and interventions in Europe
13:20
to
14:50
Insights zone 4 (I4)
Structured session
Prevention and control of infectious diseases among people who inject drugs: New evidence within the updated guidance from the ECDC and the EMCDDA
13:20
to
14:50
Networking zone 3 (N3)
Structured session
15:00
Estimating harm
15:00
to
16:30
Central square 3 (C3)
Oral presentation session
Estimating prevalence
15:00
to
16:30
Knowledge market 4 (K4)
Oral presentation session
Implementation of quality standards in drug demand reduction – where we are and where we are going?
15:00
to
16:30
Knowledge market 1 (K1)
Structured session
Injecting-related infections and drug surveillance
15:00
to
16:30
Knowledge market 3 (K3)
Oral presentation session
Towards endemicity: A global perspective of the many variants of drug consumption rooms and service models in operation
15:00
to
16:30
Insights zone 3 (I3)
Structured session
16:50
Hepatitis C prevention and treatment among people who inject drugs: Global progress and future requirements
16:50
to
18:20
Knowledge market 3 (K3)
Structured session
Improving the health of people who use drugs
16:50
to
18:20
Networking zone 4 (N4)
Short communication session
Thursday, 24 November
09:00
Contemporary Issues
09:00
to
10:30
Central square 2 (C2)
Oral presentation session
10:50
From Harm to Risk Reduction: OKANA’s 360o approach in Athens
10:50
to
12:20
Knowledge market 4 (K4)
Structured session
How can we improve global coverage of interventions to reduce drug-related harms?
10:50
to
12:20
Main stage
Structured session
New frontiers of harm reduction in drug policy
10:50
to
12:20
Networking zone 2 (N2)
e-poster guided tour
Practitioners informing practice
10:50
to
12:20
Knowledge market 3 (K3)
Oral presentation session
Successful systemic management for addiction challenges and all its side effects
10:50
to
12:20
Central square 4 (C4)
Structured session
13:20
Drug checking in supervised drug consumption room: rationale, methods and results
13:20
to
14:50
Central square 4 (C4)
Structured session
New Psychoactive Substances
13:20
to
14:50
Insights zone 4 (I4)
Oral presentation session
Uppers, downers and psychedelics
13:20
to
14:50
Networking zone 3 (N3)
Short communication session
15:00
Drug deaths: A social, structural and systems analysis
15:00
to
16:30
Knowledge market 1 (K1)
Structured session
Models to improve the health of people who inject drugs
15:00
to
16:30
Knowledge market 3 (K3)
Oral presentation session
Prevention, testing and treatment of Hepatitis C and other infections
15:00
to
16:30
Networking zone 4 (N4)
Short communication session
Preventions interventions
15:00
to
16:30
Insights zone 2 (I2)
Oral presentation session
The implementation and evaluation of “safer supply” programs in Canada as a response to an ongoing overdose crisis
15:00
to
16:30
Insights zone 4 (I4)
Structured session
16:50
Innovative approaches to tackling the drug overdoses
16:50
to
18:20
Knowledge market 1 (K1)
Oral presentation session
Reducing harm - obstacles and opportunities
16:50
to
18:20
Networking zone 1 (N1)
e-poster guided tour
18:30
On the path towards elimination of hepatitis C – Models of care to reach people who inject drugs for testing and treatment
18:30
to
19:30
Knowledge market 4 (K4)
Structured session
Friday, 25 November
10:50
Harm reduction or prevention?
10:50
to
12:20
Insights zone 2 (I2)
Oral presentation session
Portuguese Drug Policy Model. Achievements and challenges
10:50
to
12:20
Central square 2 (C2)
Structured session
Recreational drug use and risk
10:50
to
12:20
Central square 3 (C3)
Oral presentation session
13:20
Barriers in the implementation of harm reduction interventions in European prisons. From evidence to practice
13:20
to
14:50
Main stage
Structured session
Navigating the future of supervised consumption research and intervention: European and North American experiences
13:20
to
14:50
Central square 2 (C2)
Structured session
Overdose prevention
13:20
to
14:50
Knowledge market 3 (K3)
Oral presentation session
The experience of persons in homeless situation with alcohol related problems regarding a pharmacological harm reduction initiative
13:20
to
14:50
Knowledge market 4 (K4)
Structured session
Presentations
Wednesday, 23 November
10:50
Oral presentation
A qualitative exploration of patient’s experience of mobile telephone-delivered Contingency Management (mCM) to promote adherence to supervised methadone in UK pharmacies
10:50
to
12:20
Knowledge market 3 (K3)
Carol-Ann Getty
Oral presentation
I don’t chase drugs anymore and I’m not dead': The Impact of Safer Opioid Supply Programs in Ontario Canada on Client’s Health and Drug Use
10:50
to
12:20
Knowledge market 3 (K3)
Rose Schmidt
Oral presentation
Delivering telemedicine to vulnerable people with opioid use disorder: Outcomes of a program co-constructed and implemented with a community-based harm reduction service in Montreal, Canada
10:50
to
12:20
Knowledge market 3 (K3)
Stine Hoj
Oral presentation
Access to their own drugs': Navigating the drawbacks and benefits of injectable hydromorphone and diacetylmorphine treatment in Vancouver, BC
10:50
to
12:20
Knowledge market 3 (K3)
Samara Mayer
Short communication
OurFutures: A suite of universal evidence-based eHealth programs to prevent substance use and mental ill-health among adolescents
10:50
to
12:20
Networking zone 4 (N4)
Lauren Gardner
Short communication
Telegram as a space for peer-leded harm reduction communities and netreach interventions
10:50
to
12:20
Networking zone 4 (N4)
Sara Rolando
Short communication
Collaboration between prevention work and law enforcement in a nightlife drug-using setting: a vulnerable encounter?
10:50
to
12:20
Networking zone 4 (N4)
Annemie Coone
Short communication
Addressing Adherence and Success Rates of a Digital Self-Help Intervention for Alcohol and Substance Use with Machine Learning
10:50
to
12:20
Networking zone 4 (N4)
Anna Goudriaan
Short communication
What’s trending? Using social media to engage with hard to reach groups through an online survey
10:50
to
12:20
Networking zone 4 (N4)
Nicki Killeen
Short communication
Accessability of mental health services for people with substance use: findings from the SUMHIT project
10:50
to
12:20
Networking zone 4 (N4)
Jürgen Magerman
Short communication
Drug use and associated factors in Secondary Education in Basque Country
10:50
to
12:20
Networking zone 4 (N4)
Álvaro Moro Inchaurtieta
Short communication
What aspects of a drug checking service are important in a high-cost drug market?
10:50
to
12:20
Networking zone 4 (N4)
Raimondo Bruno
13:20
e-poster
A retrospective overview of polydrug abuse in Tunisia
13:20
to
14:50
Networking zone 1 (N1)
Bilel Moslah
e-poster
Professionals’ views on challenges in inpatient substance abuse treatment during COVID-19 pandemic
13:20
to
14:50
Networking zone 1 (N1)
Eeva Ekqvist
e-poster
Tipping points surrounding motivation to change substance use patterns among seniors in the general population or with incarceration experience: are they all the same?
13:20
to
14:50
Networking zone 1 (N1)
Valérie Aubut
e-poster
Methodological challenges and policy relevance of studies on substance use in nightlife settings: the case of the Nightlife Study in the Netherlands
13:20
to
14:50
Networking zone 1 (N1)
Karin Monshouwer
Oral presentation
4. The Impact of the Russian Invasion of Ukraine on Needle and Syringe Distribution by Harm Reduction Organizations
13:20
to
14:50
Insights zone 4 (I4)
Benjamin Nikitin
e-poster
Incorporating Culture into The Treatment of Substance Use Disorder: A Narrative Review
13:20
to
14:50
Networking zone 1 (N1)
Odete Nombora
Oral presentation
1. Equitable substance use treatment for migrants, refugees and ethnic minorities: An emerging research domain
13:20
to
14:50
Insights zone 4 (I4)
Inês Hasselberg
e-poster
COVID-19 related stressors and alcohol use among urban refugee youth in Kampala, Uganda
13:20
to
14:50
Networking zone 1 (N1)
Carmen Logie
Oral presentation
2. Substance use disorders in refugee and migrant groups in Sweden: A nationwide cohort study of 1.2 million people
13:20
to
14:50
Insights zone 4 (I4)
Samantha Harris
e-poster
Harm reduction calls to action from young people who use drugs on the streets of Vancouver and Lisbon
13:20
to
14:50
Networking zone 1 (N1)
Joana Canedo
Oral presentation
5. Services for vulnerable Migrants who use Drugs in the EU (SEMID-EU)
13:20
to
14:50
Insights zone 4 (I4)
Machteld Busz
Discussion
Ways forward: synthetizing priorities in prevalence studies and intervention needs in the EU
13:20
to
14:50
Insights zone 4 (I4)
Charlotte De Kock,
Klaudia Palczak
Oral presentation
3. Smartphone-based addiction prevention for young refugees: results of a feasibility study
13:20
to
14:50
Insights zone 4 (I4)
Lina-Sophia Falkenberg
e-poster
Cannabis use and aquisition in pandemic times – results from a sample of regular users in Germany
13:20
to
14:50
Networking zone 1 (N1)
Bernd Werse
Oral presentation
1. Overview of the updated ECDC/EMCDDA guidance on the prevention and control of infectious diseases among people who inject drugs
13:20
to
14:50
Networking zone 3 (N3)
Anne Bergenstrom,
Janelle Sandberg
Oral presentation
2. Effectiveness of drug treatment, needle and syringe programmes and drug consumption rooms in the prevention of blood-borne viruses among people who inject drugs – updated evidence from reviews of empirical and mathematical modelling studies
13:20
to
14:50
Networking zone 3 (N3)
Matthew Hickman
Oral presentation
3. Enhancing the HCV care cascade among people who inject drugs: a systematic review and considerations from an expert panel
13:20
to
14:50
Networking zone 3 (N3)
Ilonka Horváth
Discussion
Perspectives from government and civil society member(s) of the ECDC and EMCDDA expert panel on the key areas of intervention
13:20
to
14:50
Networking zone 3 (N3)
Janelle Sandberg,
Anne Bergenstrom,
Anna Tarján,
Mat Southwell,
Viktor Mravcik,
Annette Verster,
Slava Kushakov
15:00
Oral presentation
Fear of inpatient opioid withdrawal: Addressing a modifiable barrier to health-care access for people who use illicit opioids.
15:00
to
16:30
Knowledge market 3 (K3)
Magdalena Harris
Oral presentation
Analysis of drugs in used syringes from sentinel European cities, 2020
15:00
to
16:30
Knowledge market 3 (K3)
Thomas Seyler
Oral presentation
The impact of opioid agonist treatment on hospitalisations for injecting-related diseases: a retrospective data linkage study
15:00
to
16:30
Knowledge market 3 (K3)
Samantha Colledge-Frisby
Oral presentation
1. Quality Assurance Tools: Improving Coverage, Accessibility and Quality of Drug Use Disorder Treatment
15:00
to
16:30
Knowledge market 1 (K1)
Anja Busse
Oral presentation
4. Key factors for a successful implementation of Quality Standards in Drug Demand Reduction – a Delphi Study
15:00
to
16:30
Knowledge market 1 (K1)
Rafaela Rigoni
Oral presentation
2. Further ENhancing the Implementation of Quality Standards in drug demand reduction across Europe (FENIQS-EU) project – study objectives and first realisations
15:00
to
16:30
Knowledge market 1 (K1)
Dijana Jerkovic
Oral presentation
3. State of the Art of Quality Standards implementation in drug demand reduction in Europe
15:00
to
16:30
Knowledge market 1 (K1)
Martina Feric
Oral presentation
5. An inspiring practice example of Quality Standards implementation: the Spanish Good Practice inDemand Reduction Portal (PBBPP)
15:00
to
16:30
Knowledge market 1 (K1)
Alba González-Roz
Discussion
Quality Standards in Drug Demand Reduction – lessons learned and the way forward
15:00
to
16:30
Knowledge market 1 (K1)
Wouter Vanderplasschen
Oral presentation
Trends in mortality from alcohol, opioid, and combined alcohol and opioid poisonings by sex, educational attainment and race and ethnicity for the United States 2000-2018.
15:00
to
16:30
Central square 3 (C3)
Charlotte Buckley
Oral presentation
Mortality consequences of misuse of psychoactive prescription drugs in Portugal - the MisuMedPT project
15:00
to
16:30
Central square 3 (C3)
Ana Araújo
Oral presentation
Utilising data linkage to describe and explore mortality among a retrospective cohort of individuals admitted to residential substance use treatment.
15:00
to
16:30
Central square 3 (C3)
Tisdale Calvert
Oral presentation
It is logically not possible to quantify the number of indirect deaths
15:00
to
16:30
Central square 3 (C3)
Alfred Uhl
Oral presentation
Mortality and Morbidity in Patients in Opioid Maintenance Treatment
15:00
to
16:30
Central square 3 (C3)
Roman Gabrhelík
Oral presentation
2. The rapid expansion of DCRs/SIFs in Canada in the context of a public health emergency
15:00
to
16:30
Insights zone 3 (I3)
Jane Buxton
Oral presentation
3. Denmark: A successful case study in community advocacy culminating in several sanctioned SIFs
15:00
to
16:30
Insights zone 3 (I3)
Michael Lodberg Olsen
Oral presentation
4. How to run an unsanctioned overdose prevention van; experiences from Glasgow 2020-2021
15:00
to
16:30
Insights zone 3 (I3)
Peter H. Krykant
Discussion
Discussion: synergies and challenges each region faces in relation to the model/s within which DCRs operate
15:00
to
16:30
Insights zone 3 (I3)
Jane Mounteney
Oral presentation
1. Twenty-one years of operation at the Uniting Sydney Medically Supervised Injecting Centre (MSIC) Australia
15:00
to
16:30
Insights zone 3 (I3)
Marianne Jauncey
Oral presentation
Anabolic androgenic steroid use population size estimation: a first stage study utilising a Delphi exercise
15:00
to
16:30
Knowledge market 4 (K4)
Vivian Hope
Oral presentation
Prevalence and socio-demographics correlates of cannabis vaping: Results from the 2018 & 2019 International Cannabis Policy Study
15:00
to
16:30
Knowledge market 4 (K4)
Gary Chan
Oral presentation
Systematic review and meta-analysis of the prevalence of prescription opioid dependence in patients with chronic non cancer pain (CNCP) treated with opioid painkillers
15:00
to
16:30
Knowledge market 4 (K4)
Kyla Thomas
Oral presentation
Prevalence and factors associated with hospitalisation for bacterial skin infections among people who inject drugs: the ETHOS Engage Study
15:00
to
16:30
Knowledge market 4 (K4)
Jason Grebely
Oral presentation
How does risk prevention (not) work? Learning from the realist, pragmatic, cluster-randomised trial of the RISKIT-CJS programme (with a null result)
15:00
to
16:30
Knowledge market 4 (K4)
Nadine Hendrie
Oral presentation
Association of opioid agonist treatment with mortality or rehospitalization following injection drug use-associated bacterial and fungal infections: linkage cohort study
15:00
to
16:30
Knowledge market 3 (K3)
Thomas Brothers
16:50
Short communication
Comparison of intranasal and intramuscular naloxone in opioid overdoses managed by ambulance staff: a double dummy, randomised, controlled trial
16:50
to
18:20
Networking zone 4 (N4)
Arne Skulberg
Oral presentation
Peer and Nursing-led Outreach Combined with Point-of-care HCV Testing to Decentralise HCV Care and Enhance HCV Treatment Among People Who Use Drugs: The REACH_U Project
16:50
to
18:20
Networking zone 4 (N4)
Cristiana Merendeiro
Short communication
Monitoring overall mortality among people who are using drugs in Europe: A good practice example for international cooperation via the REITOX network
16:50
to
18:20
Networking zone 4 (N4)
Tanja Schwarz
Short communication
Developing an Intervention to Manage Benzodiazepine Dependence and High-Risk Use in the Context of Escalating Drug Related Deaths: A feasibility study
16:50
to
18:20
Networking zone 4 (N4)
Catriona Matheson
Short communication
Housing-based syringe services programs to improve access to safe injecting supplies for people who inject drugs in Vancouver, Canada: A spatially-oriented qualitative study
16:50
to
18:20
Networking zone 4 (N4)
Koharu Loulou Chayama
Short communication
Peer involvement and intersectoral cooperation experiences in outreach work with people who use psychoactive substances: a scoping review
16:50
to
18:20
Networking zone 4 (N4)
João Pedro Ramos
Short communication
Registration for opioid agonist treatment in Ireland from 1999 to 2019: positive findings in younger individuals.
16:50
to
18:20
Networking zone 4 (N4)
Peter McCarron
Short communication
The role of a medically supervised injecting room in improving access to health and social services.
16:50
to
18:20
Networking zone 4 (N4)
Nico Clark
Short communication
Barriers and facilitators for use of oral healthcare services among people with substance use disorders: A qualitative study in Norway
16:50
to
18:20
Networking zone 4 (N4)
Siv-Elin Carlsen
Oral presentation
1. Interventions to enhance prevention of hepatitis C and HIV infection
16:50
to
18:20
Knowledge market 3 (K3)
Julie Bruneau
Oral presentation
2. Treatment as prevention for hepatitis C infection: A key piece to the elimination puzzle
16:50
to
18:20
Knowledge market 3 (K3)
Matthew Hickman
Oral presentation
3. We have reached single-diagnosis and treatment for hepatitis C infection: What next?
16:50
to
18:20
Knowledge market 3 (K3)
Jason Grebely
Oral presentation
4. Community-led initiatives to enhance prevention and treatment for hepatitis C
16:50
to
18:20
Knowledge market 3 (K3)
Judy Chang
Thursday, 24 November
09:00
Oral presentation
Stakeholders’ perceptions about their position and the dynamics between the stakeholders within Swedish drug policy field
09:00
to
10:30
Central square 2 (C2)
Tuulia Lerkkanen
Oral presentation
Switching from a criminalisation to a public health approach to injecting drug use in Eastern Europe and Central Asia: a modelling analysis of the costs and impact on HIV transmission
09:00
to
10:30
Central square 2 (C2)
Zoe Ward
Oral presentation
Addressing intimate partner abuse (IPA) perpetrated by heterosexual men in substance use treatment: the ADVANCE programme
09:00
to
10:30
Central square 2 (C2)
Gail Gilchrist
Oral presentation
ROSE: A peer-led intervention to support peer workers in overdose response settings in British Columbia
09:00
to
10:30
Central square 2 (C2)
Fred Cameron
10:50
e-poster
Why Social Science should matter for a pragmatic drug policy: Critical analysis of the drug policy debate in India, 1947-2020.
10:50
to
12:20
Networking zone 2 (N2)
Kawal Deep Kour
e-poster
Alcohol industry’s arguments disseminated in the mainstream press against pregnancy alcohol warning labels in France
10:50
to
12:20
Networking zone 2 (N2)
Ana Millot
e-poster
Sin tax in Poland – an example of effectiveness of fiscal measures in alcohol policy
10:50
to
12:20
Networking zone 2 (N2)
Dagmara Lebiecka
e-poster
Myths of drug consumption decriminalization: long-term effects of Portuguese decriminalization on drug-related deaths
10:50
to
12:20
Networking zone 2 (N2)
Lucas Marín-Llanes
e-poster
The association of cannabis marketing exposure with positive cannabis attitudes and cannabis use in the most permissive medical cannabis market in the U.S.
10:50
to
12:20
Networking zone 2 (N2)
Amy Cohn
e-poster
Building harm reduction focused cannabis public education materials: An example of knowledge translation with previously stigmatized communities.
10:50
to
12:20
Networking zone 2 (N2)
Daniel Bear
e-poster
Lessons for Public Health and Public Safety from Fentanyl-Related Substances Scheduling in the United States
10:50
to
12:20
Networking zone 2 (N2)
M.J. Menendez
e-poster
20 years of decriminalisation
10:50
to
12:20
Networking zone 2 (N2)
Américo Gegaloto
Oral presentation
Medical cannabis in professional education: Assessment of students from Malta, Israel and Russia
10:50
to
12:20
Knowledge market 3 (K3)
Yuval Zolotov
Oral presentation
Primary Care Provider expectations of addiction services and patients in Spain.
10:50
to
12:20
Knowledge market 3 (K3)
Pablo Barrio
Oral presentation
Optimising take home naloxone intervention delivery in the community (retail) pharmacy setting.
10:50
to
12:20
Knowledge market 3 (K3)
Jennifer Scott
Oral presentation
Practitioner perspectives on working with older patients in opioid agonist treatment (OAT) in Norway
10:50
to
12:20
Knowledge market 3 (K3)
John Todd-kvam
Oral presentation
Integrating harm reduction in homelessness services. The HR4H Key Principles
10:50
to
12:20
Knowledge market 3 (K3)
Roberto Perez Gayo
Oral presentation
Administration matters! A retrospective cohort study of medication dispensing at pharmacies
10:50
to
12:20
Knowledge market 3 (K3)
Birgitte Thylstrup
Oral presentation
2. Streetwork and Outreach Networking
10:50
to
12:20
Knowledge market 4 (K4)
Lagakou Litsa
Oral presentation
3. Direct access to OST treatment and integrated therapy: Lessons learned from streets to community
10:50
to
12:20
Knowledge market 4 (K4)
Nikos Avgerinos
Oral presentation
4. Harm Reduction and Covid 19: Hostel 'IONIS', an example of a holistic intervention for homeless drug users
10:50
to
12:20
Knowledge market 4 (K4)
Foteini Leobilla
Discussion
Challenges faced, political will, societal willingness and community approach of the harm reduction policy.
10:50
to
12:20
Knowledge market 4 (K4)
Athanasios Theocharis
Oral presentation
1. The 4 pillar drug policy and city overview
10:50
to
12:20
Central square 4 (C4)
Andrea Weiss
Oral presentation
3. t-alk' and 'City' – low-threshold meeting places for a diverse clientele
10:50
to
12:20
Central square 4 (C4)
Larissa Stämpfli
Oral presentation
2. Surpervised drug consumption facilities (SDCF)
10:50
to
12:20
Central square 4 (C4)
Janine Lanz
Oral presentation
4. sip züri' - entry control of safe injection facilities, and from social space management to social ambulance
10:50
to
12:20
Central square 4 (C4)
Mara Brügger
Oral presentation
5. Flora Dora' and prostitution area team: outreach social work for sexworkers and low-threshold counselling on the spot
10:50
to
12:20
Central square 4 (C4)
Ursula Kocher
Oral presentation
1. Steps forward in an attempt of OKANA to widen harm reduction to risk reduction: entries and facilities within a new concept based on the real needs
10:50
to
12:20
Knowledge market 4 (K4)
Athanasios Theocharis
Oral presentation
1. Global epidemiology of injecting drug use, HIV/HCV among people who inject drugs, and coverage of interventions to reduce drug-related harms
10:50
to
12:20
Main stage
Louisa Degenhardt
Oral presentation
2. Successful models for implementation of harm reduction programmes
10:50
to
12:20
Main stage
Monica Ciupagea
Oral presentation
3. How can we improve data and mobilise funding for harm reduction support globally?
10:50
to
12:20
Main stage
Keith Sabin
Oral presentation
4. Community advocacy and community-led monitoring to improve coverage and quality of services to reduce drug-related harms
10:50
to
12:20
Main stage
Judy Chang
13:20
Oral presentation
Codesigning an Australian National Prompt Response Network for Emerging Drugs
13:20
to
14:50
Insights zone 4 (I4)
Penelope Hill
Oral presentation
Cannabis adulterated with the synthetic cannabinoid receptor agonist MDMB-4en-PINACA and the role of European drug checking services
13:20
to
14:50
Insights zone 4 (I4)
Pieter E. Oomen
Oral presentation
A qualitative study of people who use new psychoactive substances and harm reduction services in eight countries of Eastern Europe and Central Asia region
13:20
to
14:50
Insights zone 4 (I4)
Eliza Kurcevič
Oral presentation
In vitro pharmacological characterization of recent non-fentanyl synthetic opioids including 2-benzylbenzimidazole ‘nitazene’ opioids
13:20
to
14:50
Insights zone 4 (I4)
Marthe Vandeputte
Short communication
Evaluating Cracks in the Ice – a digital health initiative to support families, health workers and communities affected by crystal methamphetamine (‘ice’)
13:20
to
14:50
Networking zone 3 (N3)
Steph Kershaw
Short communication
Exclusive therapeutic use of cannabis in France: characteristics and use patterns in a large sample of daily users
13:20
to
14:50
Networking zone 3 (N3)
Martin Bastien
Short communication
Psychoactive substance use among Serbian adults – results from online survey
13:20
to
14:50
Networking zone 3 (N3)
Biljana Kilibarda
Short communication
Harm Reduction for Chemsex in Lisbon: community-based interventions for a hard-to-reach group, during the COVID-19 pandemic
13:20
to
14:50
Networking zone 3 (N3)
Filipe Couto Gomes
Short communication
Z-Drugs Dependence: An Awakening Truth
13:20
to
14:50
Networking zone 3 (N3)
Afonso Homem De Matos
Oral presentation
The added value of drug checking data in combination with data from online drug monitoring to evaluate NPS market dynamics: the case of 3-MMC in the Netherlands.
13:20
to
14:50
Insights zone 4 (I4)
Laura Smit-rigter
Oral presentation
3. Drug checking in DCRs in Switzerland: a new harm reduction tool?
13:20
to
14:50
Central square 4 (C4)
Florian Meyer,
Pierre Esseiva
Oral presentation
4. A qualitative exploration of three hypothetical models of drug checking service delivery in a Scottish context
13:20
to
14:50
Central square 4 (C4)
Danilo Falzon
Oral presentation
1. Implementing community-based drug checking services in two Canadian provinces: lessons learned and ways forward
13:20
to
14:50
Central square 4 (C4)
Karen McDonald
Oral presentation
2. Tailoring drug checking services to Drug Consumption Rooms
13:20
to
14:50
Central square 4 (C4)
Mireia Ventura
Short communication
The epigenetic effects of cannabis exposure and their link to behavior and emotional manifestations – a scoping review
13:20
to
14:50
Networking zone 3 (N3)
Ana Sofia Machado
15:00
Oral presentation
1. Why people who use drugs need a safe regulated supply of all drugs
15:00
to
16:30
Insights zone 4 (I4)
Natasha Touesnard,
Matthew Alexander Bonn
Oral presentation
3. A mixed methods evaluation of risk mitigation measures to address the dual public health crisis of COVID-19 and overdose
15:00
to
16:30
Insights zone 4 (I4)
Karen Urbanoski,
Bernie Pauly
Oral presentation
4. A sea of need – Safe opioid supply service provider accounts of implementing admission priorities
15:00
to
16:30
Insights zone 4 (I4)
Carol Strike
Oral presentation
5. Modeling safer supply programs: a qualitative evaluation of three safer opioid supply program models in British Columbia, Canada
15:00
to
16:30
Insights zone 4 (I4)
Andrew Ivsins,
Geoff Bardwell
Oral presentation
2. Implementation of safe supply alternatives during intersecting COVID-19 and overdose health emergencies in British Columbia, Canada, 2021
15:00
to
16:30
Insights zone 4 (I4)
Allison Barker
Oral presentation
Quality management in prevention of risk behaviors in school setting: a Case study from Czech republic
15:00
to
16:30
Insights zone 2 (I2)
Elizabeth Novakova
Oral presentation
Durability of anxiety, depression, and substance use prevention effects from teenage years to young adulthood: 6-year outcomes from a school-based cluster randomised controlled trial delivered in adolescence.
15:00
to
16:30
Insights zone 2 (I2)
Zachary Bryant
Oral presentation
The 7-year effectiveness of school-based alcohol use prevention from adolescence to early adulthood: An RCT of universal, selective and combined interventions.
15:00
to
16:30
Insights zone 2 (I2)
Nicola Newton
Oral presentation
Design and Evaluation of a neuroscience-based, harm reduction program to prevent alcohol and illicit substance use among late adolescents: An RCT of the Illicit Project
15:00
to
16:30
Insights zone 2 (I2)
Emily Stockings
Oral presentation
The social, material and temporal effects of extended-release buprenorphine depot treatment for opioid dependence: an Australian qualitative study
15:00
to
16:30
Knowledge market 3 (K3)
Kari Lancaster
Short communication
Harm reduction services in the Netherlands: recent developments and challenges.
15:00
to
16:30
Networking zone 4 (N4)
Nadine G.M. van Gelder
Oral presentation
Serious non-fatal and fatal opioid overdose events in a cohort of hospital patients seen by an addiction consultation service: Secondary analysis of the NavSTAR trial.
15:00
to
16:30
Knowledge market 3 (K3)
Jan Gryczynski
Oral presentation
Screening, diagnosis and treatment of infectious diseases with at-risk populations: 20 years of data from a harm reduction program managed by Ares do Pinhal in Lisbon
15:00
to
16:30
Knowledge market 3 (K3)
Filipa Barata
Oral presentation
Peer-led community based infectious disease integrated testing and linkage to care in inclusion health populations in London, UK
15:00
to
16:30
Knowledge market 3 (K3)
Julian Surey
Short communication
Transactional sex as a pathway for rising sexually transmitted infections amidst the opioid epidemic in the United States
15:00
to
16:30
Networking zone 4 (N4)
Mance Buttram
Short communication
Hepatitis C reinfection following successful direct-acting antiviral therapy among patients attending a multidisciplinary treatment centre for people who use drugs in Zurich, Switzerland
15:00
to
16:30
Networking zone 4 (N4)
Claudia Bernardini
Short communication
Individual and structural factors associated with recent hepatitis C testing in people who inject drugs: gender-based analyses of the Cosinus Cohort
15:00
to
16:30
Networking zone 4 (N4)
Ilhame Anwar
Short communication
Real-world hepatitis C treatment outcomes among people who inject drugs at the Stockholm needle exchange program, Sweden
15:00
to
16:30
Networking zone 4 (N4)
Martin Kåberg
Short communication
Educations for safer injection in the Mobile Drug Consumption Room in Lisbon
15:00
to
16:30
Networking zone 4 (N4)
Ângela Leite
Short communication
Real time surveillance on the impact of restrictions on harm reduction services to improve responsiveness and reduce harms in unprecedented times
15:00
to
16:30
Networking zone 4 (N4)
Josie Smith
Short communication
Integrating hepatitis C treatment in methadone clinic in Ukraine: perspectives of participants and providers.
15:00
to
16:30
Networking zone 4 (N4)
Tetiana Kiriazova
Oral presentation
5. Drug Policy and The Rise and Decline of Racial Stratification of Prescribing and Overdose Mortality
15:00
to
16:30
Knowledge market 1 (K1)
Brian Kelly
Oral presentation
1. Drug-related deaths among young people: a social, structural and systems autopsy
15:00
to
16:30
Knowledge market 1 (K1)
Aileen O'Gorman
Oral presentation
2. Drug-related deaths in prisons in England and Wales, 2015-2020: an examination of key trends and issues for policy and practice
15:00
to
16:30
Knowledge market 1 (K1)
Karen Duke
Oral presentation
3. The role of Primary Care in the prevention of drug-related deaths: Patient and family member perspectives
15:00
to
16:30
Knowledge market 1 (K1)
Katie Colliver
Discussion
What can a social, structural and systems analysis tell us about drug-related deaths and what are the implications for policy and addiction science?
15:00
to
16:30
Knowledge market 1 (K1)
Anne Whittaker
Oral presentation
4. The role of Primary Care in the prevention of drug-related deaths: service provider perspectives
15:00
to
16:30
Knowledge market 1 (K1)
Betsy Thom
16:50
Oral presentation
First low-threshold gender responsive residential resource for homeless people using drugs in Barcelona: descriptive evaluation of the first 6 months of activity.
16:50
to
18:20
Knowledge market 1 (K1)
Gabriela Barbaglia
Oral presentation
The limitations of decriminalization at overdose events and lessons from an evaluation in British Columbia, Canada
16:50
to
18:20
Knowledge market 1 (K1)
Alissa Greer
Oral presentation
The change in methadone dispensing requirements in England during the first wave of the COVID-19 pandemic was associated with an increase in deaths from non-prescribed methadone
16:50
to
18:20
Knowledge market 1 (K1)
Caroline Copeland
Oral presentation
Long term public health benefits and cost-effectiveness of two experimental drug consumption rooms in France
16:50
to
18:20
Knowledge market 1 (K1)
Perrine Roux
Oral presentation
The United Kingdom’s first unsanctioned safe injecting facility; a proof-of-concept evaluation
16:50
to
18:20
Knowledge market 1 (K1)
Gillian Shorter
e-poster
Knowledge and attitude of community stakeholders towards harm reduction activities including Methadone treatment, needle and syringe exchange programs for drug users and injectors in Gaza Strip-Palestine (2019)
16:50
to
18:20
Networking zone 1 (N1)
Mohammed fathi Alafifi
e-poster
High smoking and low cessation rates among patients in treatment for opioid and other substance use disorders
16:50
to
18:20
Networking zone 1 (N1)
Endre D. Bjørnestad
e-poster
Hepatitis C seroprevalence and associated factors among people who inject drugs (PWID) in Estonia
16:50
to
18:20
Networking zone 1 (N1)
Sigrid Vorobjov
e-poster
An ecological analysis of the spatial relationship between a network of supervised consumption services and overdose mortality incidence in Toronto, Canada.
16:50
to
18:20
Networking zone 1 (N1)
Indhu Rammohan
e-poster
Take-Home Naloxone and risk management among people who survived an opioid overdose; a qualitative analysis informed by drug, set and setting
16:50
to
18:20
Networking zone 1 (N1)
Elin Holmén
e-poster
Mortality and causes of death among persons with alcohol use disorder only versus persons with opioid dependence: results from a 19-year prospective cohort study.
16:50
to
18:20
Networking zone 1 (N1)
Ivar Skeie
e-poster
Identifying and tracking cases of suspected unintentional drug overdose deaths in near real-time using the Suspected Potential Overdose Tracker (SPOT)
16:50
to
18:20
Networking zone 1 (N1)
Karli Hochstatter
e-poster
Wearable technologies that may prevent, detect or respond to opioid overdose: a scoping review.
16:50
to
18:20
Networking zone 1 (N1)
Basak Tas
e-poster
Harm reduction behaviors are associated with carrying naloxone among patients on methadone treatment.
16:50
to
18:20
Networking zone 1 (N1)
Zofia Kozak
18:30
Oral presentation
Progress towards elimination of hepatitis C among people who inject drugs in Norway
18:30
to
19:30
Knowledge market 4 (K4)
Knut Boe Kielland
Oral presentation
2. HCV treatment uptake among marginalized people who inject drugs in Norway: A registry-based study
18:30
to
19:30
Knowledge market 4 (K4)
Linda Wüsthoff
Oral presentation
3. HCV treatment uptake among marginalized people who inject drugs in Norway: A registry-based study, and the Progress towards elimination of hepatitis C among people who inject drugs in Norway
18:30
to
19:30
Knowledge market 4 (K4)
Knut Boe Kielland
Oral presentation
2. Opportunistic Treatment of Hepatitis C Virus Infection: A pragmatic stepped-wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs (OPPORTUNI-C)
18:30
to
19:30
Knowledge market 4 (K4)
Olav Dalgard
Oral presentation
Opportunistic Treatment of Hepatitis C Virus Infection: A pragmatic stepped-wedge clusterrandomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs (OPPORTUNI-C)
18:30
to
19:30
Knowledge market 4 (K4)
Havard Midgard
Oral presentation
1. Hepatitis C treatment and reinfection surveillance among people who inject drugs in a low-threshold program. And new models to reach those hard to reach; results from Point of Care testing and treatment in a nurse led and a peer led mobile clinic
18:30
to
19:30
Knowledge market 4 (K4)
Linda Wüsthoff
Friday, 25 November
10:50
Oral presentation
What would it take to get people to stop rolling joints with tobacco?
10:50
to
12:20
Insights zone 2 (I2)
Adam Winstock
Oral presentation
Personas in drug use - Understanding substance-use motives in young adults
10:50
to
12:20
Insights zone 2 (I2)
Martha C de Jonge
Oral presentation
Data mining-based profiles of emerging adults at elevated risk for negative alcohol use consequences
10:50
to
12:20
Insights zone 2 (I2)
Elena Gervilla
Oral presentation
Strategic Ignorance or Counter Knowledge: 60 years of Harm Reduction Debates in Swedish Parliament
10:50
to
12:20
Insights zone 2 (I2)
Lena Eriksson
Oral presentation
Size Matters: Comparing the MDMA content and weight of ecstasy tablets submitted to European drug checking services in 2012-2021
10:50
to
12:20
Central square 3 (C3)
Ruben Vrolijk
Oral presentation
Shifting stages of ATS use and evidence-based intervention for risk reduction
10:50
to
12:20
Central square 3 (C3)
Nienke Liebregts
Oral presentation
Polydrug use typologies of regular ecstasy users visiting electronic dance music events in the United Kingdom and the Netherlands: A Latent Class Analysis.
10:50
to
12:20
Central square 3 (C3)
Ruben Van Beek
Oral presentation
Drug use and harm reduction in techno parties: some lessons learned from 20 years of fieldwork
10:50
to
12:20
Central square 3 (C3)
Fabrice Guilbaud
Oral presentation
New psychoactive substances tested by Energy Control, a community-based service of drug-checking and harm-reduction in Spain
10:50
to
12:20
Central square 3 (C3)
Adrià Quesada
Oral presentation
4. Drug consumption rooms in Lisbon: lessons learned
10:50
to
12:20
Central square 2 (C2)
Adriana Curado
Oral presentation
5. A strategy for all drug uses
10:50
to
12:20
Central square 2 (C2)
Maria Carmo Carvalho
Oral presentation
3. Harm Reduction and Public Health: The place of 'subjugated knowledges'
10:50
to
12:20
Central square 2 (C2)
Daniel Martins
Oral presentation
1. How to reduce drug-related crimes
10:50
to
12:20
Central square 2 (C2)
Jorge Quintas
Oral presentation
2. 20 years of Portuguese drug policy: developments and current challenges
10:50
to
12:20
Central square 2 (C2)
Ximene Rêgo
13:20
Oral presentation
Seven years with take-home naloxone for overdose prevention in Norway: who are the first responders and how do they perform?
13:20
to
14:50
Knowledge market 3 (K3)
Øystein Bruun Ericson
Oral presentation
Post-Overdose Outreach Programs in Massachusetts: Lessons Learned, Impact and Best Practice Guidance
13:20
to
14:50
Knowledge market 3 (K3)
Alexander Walley
Oral presentation
The impact of the WHO/UNODC S-O-S training package on opioid overdose response knowledge and attitudes
13:20
to
14:50
Knowledge market 3 (K3)
Paul Dietze
Oral presentation
Binge drug injection among people who inject drugs in Montreal: characterizing the substances and social contexts involved to inform overdose prevention efforts
13:20
to
14:50
Knowledge market 3 (K3)
Nanor Minoyan
Oral presentation
2. Hepatitis C and HIV associated risk factors among people in prison in Latvia, Lithuania, Portugal, Spain: informing interventions to prevent communicable diseases in prison setting
13:20
to
14:50
Main stage
Laura Isajeva
Oral presentation
3. The international guidance on harm reduction interventions in prisons
13:20
to
14:50
Main stage
Ehab Salah
Oral presentation
5. Harm reduction interventions and viral hepatitis elimination in prison: models of care and barriers for implementation
13:20
to
14:50
Main stage
Lara Tavoschi
Oral presentation
4. Impact, role, and prevalence of medication assisted treatment (MAT) for opioid users in European prisons
13:20
to
14:50
Main stage
Heino Stöver
Oral presentation
1. Provision of harm reduction interventions in European prisons: short overview of available services
13:20
to
14:50
Main stage
Linda Montanari
Oral presentation
3. Navigating an emergency response and collective action on the fentanyl frontlines: An ethnographic study of overdose prevention site implementation in Vancouver, Canada’s Downtown Eastside
13:20
to
14:50
Central square 2 (C2)
Ryan McNeil
Oral presentation
1. Drug consumption rooms: welfare state and social acceptance in France
13:20
to
14:50
Central square 2 (C2)
Marie Jauffret-Roustide
Oral presentation
2. Drug consumption rooms in Denmark: attitudes and experiences from local residents
13:20
to
14:50
Central square 2 (C2)
Esben Houborg
Oral presentation
4. More than overdose prevention: (Re)evaluating gender-attentive supervised consumption services
13:20
to
14:50
Central square 2 (C2)
Jade Boyd
Oral presentation
2. The experience of persons in homeless situation with alcohol related problems regarding a pharmacological harm reduction initiative
13:20
to
14:50
Knowledge market 4 (K4)
Raquel Medinas
Oral presentation
4. The role of those without a role - The perspective of non-clinical professionals in emergencyshelters on how to manage alcohol use disorder - police, security agents and cleaning staff
13:20
to
14:50
Knowledge market 4 (K4)
Ricardo Fuertes
Oral presentation
3. Amidst the most vulnerable voices: women and migrants in homeless situation with Alcohol UseDisorders (AUD)
13:20
to
14:50
Knowledge market 4 (K4)
Màrio Santos
Oral presentation
5. All we can do - Emergency Shelter' staff positioning regarding alcohol related problems in thecontext of a new harm reduction intervention
13:20
to
14:50
Knowledge market 4 (K4)
Joana Tavares
Discussion
Prison health in Europe
13:20
to
14:50
Main stage
Fadi Meroueh,
Filipa Alves da Costa
Oral presentation
1. Individuals with lived experience of homelessness and alcohol use disorders - insights from the PLACE study
13:20
to
14:50
Knowledge market 4 (K4)
Ana Neto